Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial.

Abstract

Advanced biliary tract cancer (BTC) has a poor prognosis, even after combined chemotherapy of gemcitabine and oxaliplatin (GEMOX). To investigate the efficacy and safety of GEMOX chemotherapy combining atezolizumab and bevacizumab in advanced BTC, the authors designed an open-label, single-arm, phase II clinical trial and will enroll patients with stage IV BTC. The participants will receive GEMOX chemotherapy combined with atezolizumab plus bevacizumab. The primary end point is objective response rate; the secondary end points are overall survival, disease control rate, progression-free survival, time to progression, duration of response and safety. The results of this trial are expected to provide novel, safe and effective treatment options for patients with advanced BTC, which could further improve their prognosis. Clinical Trial Registration: ChiCTR2100049830 (ChiCTR.org).

• Authors: Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng
• Journal: Future oncology (London, England) (Future Oncol) Vol. 19 Issue 15 Pg. 1029-1035 (May 2023) ISSN: 1744-8301 [Electronic] England
• PMID: 37132469 (Publication Type: Journal Article, Clinical Trial Protocol)

Chemical References

• Gemcitabine
• atezolizumab
• Oxaliplatin
• Cisplatin
• Bevacizumab

Topics

• Humans
• Gemcitabine
• Oxaliplatin (therapeutic use)
• Cisplatin (therapeutic use)
• Bevacizumab (adverse effects)
• Biliary Tract Neoplasms (drug therapy)
• Bile Duct Neoplasms (drug therapy)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)